NATS Partners with Quintiq to Solve Complex Planning Puzzle of 1,500 Employees Handling More Than 7,000 Flights Daily
NATS, the UK’s leading ANSP (air navigation service provider), has chosen Quintiq, a Dassault Systèmes brand, to overcome its rostering challenges in a highly complex planning environment. NATS manages air traffic over the UK as well as the eastern part of the Atlantic Ocean and provides ATC (air traffic control) services to 13 UK airports. With an operational workforce of 1,500 handling an average of 5,000 to 7,000 flights daily, NATS needs to ensure the allocation of the right people with the right skills at the right time. To achieve this NATS sought a solution to integrate rosters and resources to increase accuracy and make the planning process more efficient.
NATS Chief Information Officer Gavin Walker, describes the company’s current planning challenges, “Rosters follow detailed labour rules and regulations; we’re using different planning systems, many of them requiring manual input, so it’s a time-consuming process.”
“The new Quintiq planning system can support NATS’ business requirements, which includes adherence to the many layers of rostering rules found in our regulated industry. Our requirements are to perform the short-term planning up to nine months ahead as well as support the medium-term planning up to 24 months ahead. Meanwhile, the software allows fast re-planning, respecting those labour rules and regulations, should last-minute disruptions occur. The optimiser function releases planners from time-consuming work every time something changes, so that they can focus their expertise exactly where and when it’s needed.”
The Quintiq solution will be used to plan for air traffic controller officers (ATCOs), air traffic service assistants (ATSAs), and for support personnel. Employees also have non-operational duties such as project meetings and training that need to be incorporated into the rosters.
Gavin elaborates, “We chose Quintiq because they were able to accommodate our specific labour and safety regulations, training, holidays, simulation work and overtime management. The software can be configured to achieve this.”
In addition to the core roster functionality, NATS was also looking to take employee preferences into consideration with a system that can be accessed from home or via mobile. The Quintiq answer to this is a mobile application, which allows interactive communication between ATCOs or ATSAs and the planners when creating new requests or checking the status of existing requests. For employees, this means a single point of contact for all shift-related communications and tasks. Next to this, the Quintiq planning and optimisation software also provides a holistic view of resource demand and supply, reporting and scenario planning.
Rob van Egmond, CEO of Quintiq, is proud of NATS’ confidence in Quintiq, “With a highly specialised workforce in a highly regulated industry, NATS presented just the kind of complex puzzle we at Quintiq live to solve. We’ve recently made great inroads in the aviation sector where we serve some of the largest players: DFS, Fraport, Copenhagen Airports, Virgin Atlantic Airways and now NATS. We look forward to driving business efficiency across multiple planning horizons for NATS.”
NATS is the UK's leading provider of air traffic control services. It operates out of Swanwick in Hampshire, England and Prestwick in Ayrshire, Scotland. Each year, it handles 2.3 million flights and 250 million passengers in the UK airspace. Besides providing services to 13 UK airports and managing all upper airspace in the UK, it also provides services across Europe, the Middle East, Asia and North America. Find out more at nats.aero.
Every business has its supply chain planning puzzles. Some of those puzzles are large, some are complex and some seem impossible to solve. Since 1997, Quintiq has been solving each of those puzzles using a single supply chain planning and optimisation software. Today, approximately 12,000 users in over 80 countries rely on Quintiq software to plan and optimise workforces, logistics and production. Quintiq is part of Dassault Systèmes (Euronext Paris: #13065, DSY.PA) and has headquarters in the Netherlands and the USA, and offices around the world.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20 | Pressemelding
Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to
Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31 | Pressemelding
Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom